Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01572480 |
|
Recruitment Status
:
Recruiting
First Posted
: April 6, 2012
Last Update Posted
: March 2, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
- Multiple myeloma is a blood cancer that affects the plasma cells. These cells help produce antibodies and fight infection. Smoldering multiple myeloma (SMM) is a related condition that may develop into multiple myeloma. The current standard of care for SMM is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for SMM itself. One possible treatment involves a combination of cancer treatment drugs.
- Lenalidomide is a drug that may help reduce or prevent the growth of cancer cells. Dexamethasone is a steroid that is often given with other anti-cancer drugs. These two drugs are an approved treatment for multiple myeloma that has not responded to at least one other treatment. Carfilzomib is an experimental drug that has been effective in treating multiple myeloma. Researchers want to combine these three drugs to see if they are a safe and effective treatment for SMM.
Objectives:
- To see if carfilzomib, lenalidomide, and dexamethasone are a safe and effective treatment for smoldering multiple myeloma.
Eligibility:
- Individuals at least 18 years of age who have SMM that is likely to progress to multiple myeloma.
Design:
- Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and baseline bone marrow scans. Bone marrow samples will also be collected.
- Participants will have eight 28-day cycles of treatment with the three study drugs. The drugs will be given as tablets or as infusions. Treatment will be monitored with frequent blood tests and study visits.
- After the first four cycles, participants who are eligible for a stem cell transplant will have their stem cells collected and stored for future use.
- At the end of eight cycles, participants whose disease has not progressed will have up to 12 more cycles of treatment with lenalidomide tablets alone.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Multiple Myeloma | Drug: Carfilzomib Drug: Revlimid Drug: Dexamethasone | Phase 2 |
Show Detailed Description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study |
| Study Start Date : | March 28, 2012 |
| Estimated Primary Completion Date : | September 1, 2019 |
| Estimated Study Completion Date : | September 1, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: A
Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)
|
Drug: Carfilzomib
Carfilzomib (IV) 20-36 mg/m2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
Drug: Revlimid
Revlimid (PO) 25 mg/day, days 1 21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
Drug: Dexamethasone
Dexamethasone (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
|
|
Experimental: B
Carfilzomib (IV, Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (PO, Days 1-21 of the 28-daycycle); and, Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle)
|
Drug: Carfilzomib
Carfilzomib (IV) 20-36 mg/m2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
Drug: Revlimid
Revlimid (PO) 25 mg/day, days 1 21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
Drug: Dexamethasone
Dexamethasone (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
|
- Response Rate [ Time Frame: 8 months ]VGPR decline/response rate will be assessed using simple two-sided 90% confidence intervals at the evaluation time points
- Progression Free Survival [ Time Frame: at time of disease progression ]
- Duration of Response [ Time Frame: at time of disease progression ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Patients must have histologically or cytologically confirmed Smoldering Multiple Myeloma confirmed by the Laboratory of Pathology, NCI or the Department of Laboratory Medicine, CC based on the International Myeloma Working Group Criteria:
- Serum M-protein greater than or equal to 3 g/dl and/or bone marrow plasma cells greater than or equal 10% and <60%
- Absence of anemia: Hemoglobin >10 g/dl
- Absence of renal failure: serum creatinine < 2.0 mg/dL Absence of hypercalcemia: Ca <10.5 mg/dl
- Absence of lytic bone lesion on X-ray, CT, or PET/CT and not more than 1 lesion on spinal MRI
- Involved-un-involved light chain ratio must be <100
Measurable disease within the past 4 weeks defined by any one of the following:
- Serum monoclonal protein greater than or equal to 1.0 g/dl
- Urine monoclonal protein >200 mg/24 hour
- Serum immunoglobulin free light chain >10 mg/dL AND abnormal kappa/lambda ratio
Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of carfilzomib in combination with lenalidomide in patients <18 years of age, children are excluded from this study, but may be eligible for future pediatric trials.
ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
Patients must have normal organ and marrow function as defined below:
- absolute neutrophil count greater than or equal to1.0 K/uL
- platelets greater than or equal to75 K/uL
- hemoglobin greater than or equal to 8 g/dL(transfusions are permissible)
- total bilirubin less than or equal to 1.5 times institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) less than or equal to 3.0 times institutional upper limit of normal
- Creatinine Clearance greater than or equal to 60 ml/min. CrCl will be calculated by Cockcroft Gault method. CrCl (calculated) = (140 Age) times Mass (in kilograms) times [0.85 if Female] 72 times Serum Creatinine (in mg/dL). If calculated CrCl based on Cockcroft-Gault method is <60 mL/min, patient will have a 24 hr urine collection to measure CrCl. The measured CrCl must also be greater than or equal to 60 ml/min.
In addition to having SMM, patients must also be classified as high-risk SMM per Mayo Clinic or Spanish PETHEMA criteria
Criteria set forward by Rajkumar, Landgren, Mateos may also be used to define high risk disease, namely clonal bone marrow plasma cells greater than or equal to 10% and any one or more of the following:
- Serum M protein greater than or equal to 30g/L
- IgA SMM
- Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes
- Serum involved/uninvolved FLC ratio greater than or equal to 8 (but less than 100)
- Progressive increase in M protein level (evolving type of SMM; increase in serum M protein by greater than or equal to 25% on 2 successive evaluations within a 6-month period)
- Clonal BMPCs 50%-60%
- Abnormal PC immunophenotype (greater than or equal to 95% of BMPCs are clonal) and reduction of greater than or equal to 1 uninvolved immunoglobulin isotypes
- t(4;14) or del(17p) or 1q gain
- Increased circulating PCs
- MRI with diffuse abnormalities or 1 focal lesion
- PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction
All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist.
The effects of carfilzomib and lenalidomide on the developing human fetus are unknown. For this reason and because immunomodulatory agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Ability of subject to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
Patients who are receiving any other investigational agents.
Concurrent systemic treatment or prior therapy within 4 weeks for SMM
- Treatment with corticosteroids for other indications is permitted
Patients with a diagnosis of MM as defined by the 2014 IMWH diagnostic criteria.
Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide.
Uncontrolled hypertension or diabetes
Pregnant or lactating females. Pregnant women are excluded from this study because Carfilzomib/Lenalidomide are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Carfilzomib/Lenalidomide, breastfeeding should be discontinued if the mother is treated with Carfilzomib/Lenalidomide. These potential risks may also apply to other agents used in this study
Significant cardiovascular disease with NYHA Class II, III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction within 3 months prior to enrollment, or unstable angina, or unstable arrhythmia
Active hepatitis B or C infection
Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption
Significant neuropathy >Grade 2 at the time of first dose or within 14 days of enrollment
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations within 2 weeks that would limit compliance with study requirements.
History of other malignancy (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma) except if the patient has been free of symptoms and without active therapy during at least 5years
Major surgery within 1 month prior to enrollment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01572480
| Contact: Maureen E Edgerly, R.N. | (240) 760-6013 | edgerlym@pbmac.nci.nih.gov | |
| Contact: Dickran G Kazandjian, M.D. | (301) 451-2677 | dickran.kazandjian@nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 | |
| Principal Investigator: | Dickran G Kazandjian, M.D. | National Cancer Institute (NCI) |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT01572480 History of Changes |
| Other Study ID Numbers: |
120107 12-C-0107 |
| First Posted: | April 6, 2012 Key Record Dates |
| Last Update Posted: | March 2, 2018 |
| Last Verified: | December 17, 2017 |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
|
Proteasome Inhibitor Immunomodulatory Agents Combination Therapy |
Anti-Myeloma Activity Smoldering Multiple Myeloma SMM |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone acetate |
Dexamethasone Lenalidomide BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors |